Skip to main content

Advertisement

SpringerLink
Log in

Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Sequential use of endocrine agents is common in estrogen receptor (ER)-positive metastatic breast cancer (MBC). In premenopausal women with MBC, tamoxifen and/or a luteinizing hormone-releasing hormone (LH-RH) agonist are options for endocrine treatment. Meta-analysis showed that the combination of the two agents is superior to either monotherapy. Under ovarian ablation or function-suppression, an agent used to treat postmenopausal women, such as the aromatase inhibitor (AI), fulvestrant, becomes possible as a subsequent therapy. In postmenopausal women, endocrine treatment options are widely available and an optimal sequence has not yet to be determined. Options for first-line therapy of metastatic disease include an AI for women who have received adjuvant tamoxifen, or tamoxifen for patients who have received adjuvant AI. In addition, data suggest that fulvestrant is a promising therapeutic option that has proven efficacy in the treatment of postmenopausal women with MBC. Other agents that may be used in the sequence include a steroidal AI or a progestin. Furthermore, estrogen additive therapy by with diethylstilbestrol or ethinylestradiol has recently been revived and showed a high response rate as a salvage endocrine therapy, although its mechanism of action is still unclear. Thus, sequential use of endocrine therapies, especially the use of a subsequent therapy with a different mechanism of action to the prior therapy, has a beneficial effect in maintaining a good quality of life and extending survival for MBC with hormone responsiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Iwase H, Kurebayashi J, Tsuda H et al (2010) Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. (Translated from Eng). Breast Cancer 17(2):118–124 (in Eng)

    Article  PubMed  Google Scholar 

  2. Crump M, Sawka CA, DeBoer G et al (1997) An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. (Translated from Eng). Breast Cancer Res Treat 44(3):201–210 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  3. Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. (Translated from Eng). J Clin Oncol 19(2):343–353 (in Eng)

    CAS  PubMed  Google Scholar 

  4. Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (Translated from Eng). J Natl Cancer Inst 92(11):903–911 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  5. Boccardo F, Rubagotti A, Perrotta A et al (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. (Translated from Eng). Ann Oncol 5(4):337–342 (in Eng)

    CAS  PubMed  Google Scholar 

  6. Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. (Translated from Eng). J Clin Oncol 16(3):994–999 (in Eng)

    CAS  PubMed  Google Scholar 

  7. Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. (Translated from Eng). Br J Cancer 90(3):590–594 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Carlson RW, Theriault R, Schurman CM et al (2010) Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. (Translated from Eng). J Clin Oncol 28(25):3917–3921 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  9. Nishimura R, Anan K, Yamamoto Y et al (2013) Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. (Translated from Eng). Oncol Rep 29(5):1707–1713 (in Eng)

    PubMed Central  CAS  PubMed  Google Scholar 

  10. Bartsch R, Bago-Horvath Z, Berghoff A et al (2012) Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. (Translated from Eng). Eur J Cancer 48(13):1932–1938 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  11. Willemse PH, van der Ploeg E, Sleijfer DT et al (1990) A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. (Translated from Eng). Eur J Cancer 26(3):337–343 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  12. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. (Translated from Eng). J Clin Oncol 18(22):3758–3767 (in Eng)

    CAS  PubMed  Google Scholar 

  13. Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. (Translated from Eng). J Clin Oncol 18(22):3748–3757 (in Eng)

    CAS  PubMed  Google Scholar 

  14. Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. (Translated from Eng). Cancer 92(9):2247–2258 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  15. Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. (Translated from Eng). J Clin Oncol 21(11):2101–2109 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  16. Paridaens RJ, Dirix LY, Beex LV et al (2008) Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. (Translated from Eng). J Clin Oncol 26(30):4883–4890 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. (Translated from Eng). J Natl Cancer Inst 98(18):1285–1291 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  18. Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. (Translated from Eng). J Clin Oncol 22(9):1605–1613 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  19. Robertson JF, Llombart-Cussac A, Rolski J et al (2009) Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. (Translated from Eng). J Clin Oncol 27(27):4530–4535 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  20. Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. (Translated from Eng). N Engl J Med 367(5):435–444 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Bergh J, Jonsson PE, Lidbrink EK et al (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. (Translated from Eng). J Clin Oncol 30(16):1919–1925 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  22. Buzdar AU, Jonat W, Howell A et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. (Translated from Eng). Cancer 83(6):1142–1152 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  23. Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. (Translated from Eng). J Clin Oncol 16(2):453–461 (in Eng)

    CAS  PubMed  Google Scholar 

  24. Buzdar A, Douma J, Davidson N et al (2001) Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. (Translated from Eng). J Clin Oncol 19(14):3357–3366 (in Eng)

    CAS  PubMed  Google Scholar 

  25. Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (Translated from Eng). J Clin Oncol 18(7):1399–1411 (in Eng)

    CAS  PubMed  Google Scholar 

  26. Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. (Translated from Eng). Eur J Cancer 39(16):2318–2327 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  27. Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. (Translated from Eng). Cancer 98(2):229–238 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  28. Lonning PE, Bajetta E, Murray R et al (2000) Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. (Translated from Eng). J Clin Oncol 18(11):2234–2244 (in Eng)

    CAS  PubMed  Google Scholar 

  29. Iaffaioli RV, Formato R, Tortoriello A et al (2005) Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. (Translated from Eng). Br J Cancer 92(9):1621–1625 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Steele N, Zekri J, Coleman R et al (2006) Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. (Translated from Eng). Breast 15(3):430–436 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  31. Thurlimann B, Robertson JF, Nabholtz JM et al (2003) Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. (Translated from Eng). Eur J Cancer 39(16):2310–2317 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  32. Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. (Translated from Eng). J Clin Oncol 26(10):1664–1670 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  33. Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. (Translated from Eng). J Clin Oncol 28(30):4594–4600 (in Eng)

    Article  PubMed  Google Scholar 

  34. Yamamoto Y, Ishikawa T, Hozumi Y et al (2013) Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. (Translated from Eng). BMC Cancer 13:239 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. (Translated from Eng). Adv Ther 30(10):870–884 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Johnston SR, Kilburn LS, Ellis P et al (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. (Translated from Eng). Lancet Oncol 14(10):989–998 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  37. Manni A, Arafah BM, Pearson OH (1981) Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. (Translated from Eng). Cancer 48(11):2507–2509 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  38. Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. (Translated from Eng). J Clin Oncol 15(9):3141–3148 (in Eng)

    CAS  PubMed  Google Scholar 

  39. Paterson AH, Hanson J, Pritchard KI et al (1990) Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. (Translated from Eng). Semin Oncol 17((6 Suppl 9)):52–62 (in Eng)

    CAS  PubMed  Google Scholar 

  40. Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease. (Translated from Eng). Br Med J 2(4368):393–398 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Peethambaram PP, Ingle JN, Suman VJ et al (1999) Randomized trial of diethylstilbestrol vs tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. (Translated from Eng). Breast Cancer Res Treat 54(2):117–122 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  42. Lonning PE, Taylor PD, Anker G et al (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. (Translated from Eng). Breast Cancer Res Treat 67(2):111–116 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  43. Agrawal A, Robertson JF, Cheung KL (2006) Efficacy and tolerability of high dose “ethinylestradiol” in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. (Translated from Eng). World J Surg Oncol 4:44 (in Eng)

    Article  PubMed Central  PubMed  Google Scholar 

  44. Mahtani RL, Stein A, Vogel CL (2009) High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. (Translated from Eng). Clin Ther 31(Pt 2):2371–2378 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  45. Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. (Translated from Eng). JAMA 302(7):774–780 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. (Translated from Eng). Br J Cancer 109(6):1537–1542 (in Eng)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Li S, Shen D, Shao J et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. (Translated from Eng). Cell Rep 4(6):1116–1130 (in Eng)

    Article  CAS  PubMed  Google Scholar 

  48. Jordan VC, Lewis-Wambi JS, Patel RR et al (2009) New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. (Translated from Eng). Breast 18(Suppl 3):S10–17 (in Eng)

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The author and his immediate family members declare their conflicts of interest as follows: employment, not applicable (N/A); leadership, N/A; consultant, N/A; stock, N/A; honoraria, AstraZeneca; research funds, Chugai-Roche,AstraZeneca, Novartis, Taiho, Takeda; testimony, N/A; other, N/A.

Author information

Authors and Affiliations

  1. Department of Breast and Endocrine Therapy, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan

    Hirotaka Iwase & Yutaka Yamamoto

Authors
  1. Hirotaka Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirotaka Iwase.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iwase, H., Yamamoto, Y. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Int J Clin Oncol 20, 253–261 (2015). https://doi.org/10.1007/s10147-015-0793-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0793-8

Keywords

Search

Navigation